v3.23.1

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
License and collaboration revenue—related party	$ 82,000	$ 26,907
Operating expenses:
Research and development	103,273	88,979
General and administrative	30,969	28,984
Total operating expenses	134,242	117,963
Operating loss	(52,242)	(91,056)
Other income, net	1,458	199
Loss before provision for income taxes	(50,784)	(90,857)
Provision for income taxes	135	15
Net loss	$ (50,919)	$ (90,872)
Net loss per share, basic (in dollars per share)	$ (0.99)	$ (1.82)
Net loss per share, diluted (in dollars per share)	$ (0.99)	$ (1.82)
Weighted-average common shares outstanding, basic (in shares)	51,676	49,931
Weighted-average common shares outstanding, diluted (in shares)	51,676	49,931
Comprehensive loss:
Net loss	$ (50,919)	$ (90,872)
Other comprehensive loss:
Unrealized loss on available-for-sale securities	(439)	(221)
Comprehensive loss	$ (51,358)	$ (91,093)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Jounce Therapeutics, Inc. 10-K/A